ArticleEJNMMI research2017
Article in EJNMMI research, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 93 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
93 citing papers in PubMed, 195 citations in OpenAlex.
- First ex-vivo positronium imaging of tissues with modular J-PET scanner usingZeitschrift fur medizinische Physik · 2026Article
- Fractionation gives therapeutic benefit in animal model of [EJNMMI research · 2026Article
- Investigating the Theranostic Potential of Elementally Matched [Molecular pharmaceutics · 2026Article
- Evaluation of Bifunctional, PSMA-Targeted Triazamacrocycle-Picolinates Compatible with theJournal of medicinal chemistry · 2025Article
- Cytotoxicity and cell cycle changes in prostate cancer cells with differing PSMA expression and p53 status after treatment with PSMA-targeting radioligand [Scientific reports · 2025Article
- Therapeutic evaluation of [European journal of nuclear medicine and molecular imaging · 2025Article
- Pharmacokinetics study of FT-FAPI, a novel multi-nuclide label-able FAP targeting tracer, in mice and healthy volunteers.European journal of nuclear medicine and molecular imaging · 2025Article
- Design and characterization of a novel prostate-specific membrane antigen-targeted radioligand modified with a fatty acid albumin binder for optimized circulation half-life.EJNMMI radiopharmacy and chemistry · 2025Article
- Exploring the Therapeutic Potential ofInternational journal of molecular sciences · 2025Article
- Synthesis and In Vitro Evaluation of a Scandium-44 Radiolabeled Nanobody as a PD-L1 PET Imaging Probe.Pharmaceutics · 2025Article
- Enhancing the radionuclide theranostic concept through the radiohybrid approach.RSC medicinal chemistry · 2025Review
- Current Status and Future Perspectives of Nuclear Medicine in Prostate Cancer from Imaging to Therapy: A Comprehensive Review.Biomedicines · 2025Review
- Preclinical comparison of (radio)lanthanides using mass spectrometry and nuclear imaging techniques: biodistribution of lanthanide-based tumor-targeting agents and lanthanides in ionic form.European journal of nuclear medicine and molecular imaging · 2025Article
- First positronium lifetime imaging with scandium-44 on a long axial field-of-view PET/CT.Frontiers in nuclear medicine · 2025Article
- Development and evaluation of a single domain antibody targeting folate receptor alpha for radioligand therapy.Journal of nanobiotechnology · 2024Article
- Production of high purityEJNMMI radiopharmacy and chemistry · 2024Article
- Comparative analysis of positron emitters for theranostic applications based on small bioconjugates highlightingEJNMMI physics · 2024Article
- Iodinated PSMA Ligands as XFI Tracers for Targeted Cell Imaging and Characterization of Nanoparticles.International journal of molecular sciences · 2024Article
- Positronium image of the human brain in vivo.Science advances · 2024Article
- Comparison of the dosimetry of scandium-43 and scandium-44 patient organ doses in relation to commonly used gallium-68 for imaging neuroendocrine tumours.EJNMMI physics · 2024Article
33 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe targeting of the prostate-specific membrane antigen (PSMA) is of particular interest for radiotheragnostic purposes of prostate cancer. Radiolabeled PSMA-617, a 1,4,7,10-tetraazacyclododecane-N,N',N'',N'''-tetraacetic acid (DOTA)-functionalized PSMA ligand, revealed favorable kinetics with high tumor uptake, enabling its successful application for PET imaging (
results
conclusionsThe in vitro characteristics and in vivo kinetics of
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.